Clinical trial
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome
NCT00003415 · University of Arizona, Other · Completed
Key facts
| NCT number | NCT00003415 |
|---|---|
| Title | Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome |
| Official title | Phase I/II Study of Combined Treatment With Amifostine (Ethyol) and Topotecan (Hycamtin MS) in Patients With Myelodysplastic Syndrome |
| Lead sponsor | University of Arizona, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, topotecan hydrochloride |
| Enrollment | 26 |
| Start date | Sep 1, 1998 |
| Completion | Nov 1, 2002 |
| First posted | Aug 3, 2004 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: